Who Paid My Doc
Raza Jafry
Rheumatology Fort Worth, TX Medical Doctor
NPI 1073629986 CMS profile 934811
1400 S Main St Ste 502, Fort Worth, TX 76104
General payments
$398
Research payments
$1,010
Ownership & investment interest
$0
Research they led as principal investigator
$413,916
Through program year 2025, Raza Jafry of Fort Worth, TX is reported in the CMS Open Payments database as having received $398 across 17 general payments and $1,010 in research payments paid to them. Separately, studies naming them as principal investigator received $413,916 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 42nd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $62 | 3 | |
| 2023 | Research | $1,010 | 7 | |
| 2022 | General | $18 | 1 | |
| 2020 | General | $26 | 2 | |
| 2019 | General | $292 | 11 |
Beside peers
- Raza Jafry
- Rheumatology median
- Middle half of Rheumatology
- National median
In program year 2025, general payments to Raza Jafry were reported at $62. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.
Show as a table
| Year | Raza Jafry | Rheumatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $292 | $744 | $153–$2,687 | $163 |
| 2020 | $26 | $462 | $98–$2,027 | $114 |
| 2021 | $0 | $531 | $101–$2,153 | $132 |
| 2022 | $18 | $627 | $125–$2,303 | $149 |
| 2023 | $0 | $741 | $145–$2,524 | $160 |
| 2024 | $0 | $830 | $166–$2,660 | $164 |
| 2025 | $62 | $903 | $171–$2,775 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
1,332
Drug cost
$2,880,442
Branded share of claims
50.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Enbrel Sureclick Etanercept | Brand | 176 | $1,361,581 | |
| Orencia Clickject Abatacept | Brand | 114 | $645,115 | |
| Humira(Cf) Pen Adalimumab | Brand | 91 | $625,480 | |
| Benlysta Belimumab | Brand | 24 | $111,202 | |
| Orencia Abatacept | Brand | 13 | $74,418 | |
| Actemra Tocilizumab | Brand | 12 | $28,989 | |
| Hydroxychloroquine Sulfate | Generic | 440 | $12,006 | |
| Mycophenolate Mofetil | Generic | 50 | $7,240 | |
| Sulfasalazine Dr Sulfasalazine | Brand | 78 | $5,610 | |
| Methotrexate Methotrexate Sodium | Brand | 128 | $3,495 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 5 billing codesPaid by Medicare
$11,894
Medicare patients
88
Services billed
178
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Chronic kidney disease | 47% | |
| Diabetes | 42% | |
| Depression | 32% | |
| Heart failure | 30% | |
| COPD | 24% | |
| Ischemic heart disease | 23% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
24 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Rheumatology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.